Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (51-60 of 687) with videos related to

Pageof 69
Sort By:
European Journal of Heart Failure|November 13, 2023
The use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessmentBertram Pitt, Faiez Zannad
Journal of Cardiovascular Pharmacology|May 12, 2009
Loop diuretics in patients with heart failure: time to change to torsemide?Bertram Pitt, John Nicklas
Circulation|December 11, 2002
A lifetime of prevention: the case of heart failureSalim Yusuf, Bertram Pitt
The Medical Clinics of North America|April 16, 2003
Aldosterone as a target in congestive heart failureSanjay Rajagopalan, Bertram Pitt
European Journal of Heart Failure|November 22, 2011
Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trialBertram Pitt, Mihai Gheorghiade
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)Curt Furberg, Bertram Pitt
European Heart Journal|February 4, 2017
The association between serum potassium and mortality in patients with hypertension: 'a wake-up call'Bertram Pitt, Patrick Rossignol
Expert Opinion on Drug Safety|April 19, 2018
The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemiaBertram Pitt, Dahlia Garza
European Journal of Heart Failure|May 29, 2014
Geographic variation in heart failure trials: time for scepticism?Bertram Pitt, Mihai Gheorghiade
European Journal of Heart Failure|February 22, 2022
Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?Patrick Rossignol, Bertram Pitt
Pageof 69

Showing results (51-60 of 687) with videos related to

Sort By:
Pageof 69
European Journal of Heart Failure|November 13, 2023
The use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessmentBertram Pitt, Faiez Zannad
Journal of Cardiovascular Pharmacology|May 12, 2009
Loop diuretics in patients with heart failure: time to change to torsemide?Bertram Pitt, John Nicklas
Circulation|December 11, 2002
A lifetime of prevention: the case of heart failureSalim Yusuf, Bertram Pitt
The Medical Clinics of North America|April 16, 2003
Aldosterone as a target in congestive heart failureSanjay Rajagopalan, Bertram Pitt
European Journal of Heart Failure|November 22, 2011
Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trialBertram Pitt, Mihai Gheorghiade
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)Curt Furberg, Bertram Pitt
European Heart Journal|February 4, 2017
The association between serum potassium and mortality in patients with hypertension: 'a wake-up call'Bertram Pitt, Patrick Rossignol
Expert Opinion on Drug Safety|April 19, 2018
The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemiaBertram Pitt, Dahlia Garza
European Journal of Heart Failure|May 29, 2014
Geographic variation in heart failure trials: time for scepticism?Bertram Pitt, Mihai Gheorghiade
European Journal of Heart Failure|February 22, 2022
Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?Patrick Rossignol, Bertram Pitt
Pageof 69